Amid Tariff Storm, Multinational Pharma Giants Announce Massive U.S. Manufacturing Investments

　　【Pharmaceutical Network Industry Dynamics】In the global economic landscape, tariff policies act as an invisible yet powerful hand, profoundly influencing the development direction of various industries. Multinational pharmaceutical companies are no exception. In 2025, as the U.S. tariff policy continues to evolve, multinational pharmaceutical companies are taking actions to address potential cost increases and supply chain risks, with a series of large-scale investment plans surfacing one after another.
 

In February 2025, Eli Lilly and Company announced that it would invest a whopping $27 billion in building four new manufacturing plants in the United States over the next five years. This move brings its total manufacturing investment in the U.S. in recent years to over $50 billion. Three of the new plants will focus on small molecules.Active Pharmaceutical Ingredients (API)The production includes the active pharmaceutical ingredient (API) for the popular weight-loss drug tirzepatide. The other facility is dedicated to the production of injectables. This strategic move by Eli Lilly is clearly aimed at strengthening its supply chain within the United States, reducing reliance on imported APIs, and thereby mitigating the risk of cost spikes that could arise from potential tariff increases.
 

Almost at the same time, Novo Nordisk also quickly followed up by announcing an additional investment of $4.1 billion to expand its plant in North Carolina. This move aims to significantly increase the production capacity of its blockbuster products, such as the weight-loss drug Wegovy and the diabetes treatment Ozempic. Novo Nordisk's expansion plan is not only a response to the growing market demand but also a strategic step to ensure controllable product costs and stable supply under the shadow of tariffs. By expanding its production scale within the United States, Novo Nordisk can reduce the impact of tariff fluctuations on imported raw materials or finished products, thereby maintaining stable pricing and market competitiveness.
 

Johnson & Johnson is equally unwilling to lag behind, recently announcing that it will invest over $55 billion in its pharmaceutical and medical technology businesses in the United States over the next four years—an increase of 25% compared to the previous four years. This substantial funding will be used to build three new manufacturing facilities and expand some of the existing plants. Johnson & Johnson's investment plan covers multiple areas including the construction of R&D infrastructure and technology upgrades, aiming to comprehensively enhance its competitiveness in the U.S. market. Additionally, by strengthening local production, the company seeks to mitigate any potential negative impacts caused by tariff policies.
 

Merck & Co. is also taking active steps by opening a new pharmaceutical factory in Durham, North Carolina, worth approximately $1 billion and has laid out ambitious plans to cumulatively invest $8 billion in the U.S. by 2028. These moves indicate that Merck & Co. is committed to expanding its domestic production scale and optimizing supply chain structure to address potential tariff risks, ensuring stable supply and price competitiveness of its products in the U.S. market.
 

Pfizer Takes a Different Approach: Plan to Relocate Some European Production Bases to Existing U.S. Plants to Fully Utilize Capacity Flexibility Across Its 13 Domestic Factories in the U.S.
 

In a statement on April 10, Novartis clearly announced its plan to invest $23 billion in U.S. infrastructure over the next five years, aiming to produce all of its critical drugs for American patients within the United States. This strategic decision not only demonstrates Novartis' high regard for the U.S. market but also serves as a crucial measure to address tariff policies and ensure supply chain security.
 

These large-scale investments and strategic layout adjustments by multinational pharmaceutical companies are closely related to U.S. tariff policies. The United States has always paid close attention to the stability of the pharmaceutical industry's supply chain and domestic production capacity. Although pharmaceuticals have not yet been fully included in the high-tariff category, pharmaceutical companies are well aware of the significant uncertainty in tariff policies. If high tariffs were imposed on imported active pharmaceutical ingredients or finished drugs, it would significantly increase production costs, squeeze profit margins, and could even lead to product shortages.
 

Moreover, the call for the return of the pharmaceutical industry in the United States is growing louder, with a series of policy measures being implemented to encourage pharmaceutical companies to invest and build factories domestically. Against this backdrop, multinational pharmaceutical enterprises are responding by increasing their production layout within the U.S., which not only meets America’s expectations for industrial return but also effectively reduces tariff risks, ensuring stable business growth in the U.S., the world's largest pharmaceutical market. On a deeper level, these actions represent the proactive adaptation and strategic positioning of pharmaceutical companies amid the restructuring of the global supply chain. By strengthening local production capabilities, they enhance the resilience and risk resistance of their supply chains.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.